Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

BACKGROUND: Angiomyolipomas in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis are associated with mutations in tuberous sclerosis genes resulting in constitutive activation of the mammalian target of rapamycin (mTOR). The drug sirolimus suppresses mTOR signaling. M...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bissler, John J., McCormack, Francis X., Young, Lisa R., Elwing, Jean M., Chuck, Gail, Leonard, Jennifer M., Schmithorst, Vincent J., Laor, Tal, Brody, Alan S., Bean, Judy, Salisbury, Shelia, Franz, David N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2008
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3398441/
https://ncbi.nlm.nih.gov/pubmed/18184959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa063564
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak